Protagenic Therapeutics, Inc.\new Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Protagenic Therapeutics, Inc.\new (PTIX) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -81.40% for the 12-month period ending 2026-03-31, per its 10-K filed 2026-08-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-08-14
- Protagenic Therapeutics, Inc.\new effective income tax rate reconciliation, other adjustments, percent for fiscal 2026 was -81.40%.
- Protagenic Therapeutics, Inc.\new effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.00%.
- Protagenic Therapeutics, Inc.\new effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.00%.
- Protagenic Therapeutics, Inc.\new effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2026-03-31 | -81.40% 10-K · filed 2026-08-14 |
| 2024-12-31 | 0.00% 10-K · filed 2025-03-31 |
| 2023-12-31 | 0.00% 10-K · filed 2025-03-31 |
| 2022-12-31 | 0.00% 10-K/A · filed 2024-05-14 |
| 2021-12-31 | 0.00% 10-K · filed 2023-03-31 |
| 2020-12-31 | 0.00% 10-K · filed 2022-04-07 |
| 2019-12-31 | 0.00% 10-K · filed 2021-03-25 |
| 2018-12-31 | 0.00% 10-K · filed 2020-04-29 |
| 2017-12-31 | 0.00% 10-K · filed 2019-03-29 |
| 2016-12-31 | 6.80% 10-K · filed 2018-04-02 |
| 2015-12-31 | 1.10% 10-K/A · filed 2017-05-08 |
| 2015-06-30 | 7.10% 10-K · filed 2015-09-25 |
| 2014-12-31 | 0.00% 8-K/A · filed 2016-07-12 |
| 2014-06-30 | 0.00% 10-K · filed 2015-09-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |